Search

Search Results

1. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review

   Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the preferred regimen for patients with hormone receptor-positive and human epidermal growth...

   Melody Zhao, Kent A. Hanson, ... Ashley S. Cha-Silva in Targeted Oncology

   Article Open access 19 April 2023
   

2. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

   Objective

   The clinical efficacy and safety of sorafenib in patients with advanced liver cancer (ALC) were evaluated based on transarterial...

   Daolin Zeng, Chunlin Yu, ... Linlong Xu in World Journal of Surgical Oncology

   Article Open access 12 April 2024
   

3. Signaling pathways in rheumatoid arthritis: implications for targeted therapy

   Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function,...

   Qian Ding, Wei Hu, ... Yi Zhun Zhu in Signal Transduction and Targeted Therapy

   Article Open access 17 February 2023
   

4. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

   Radiotherapy combined with immune checkpoint blockade holds great promise for synergistic antitumor efficacy. Targeted radionuclide therapy delivers...

   Liang Zhao, Yizhen Pang, ... Haojun Chen in Signal Transduction and Targeted Therapy

   Article Open access 03 June 2024
   

5. Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

   Background

   Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies, representing less than 5% of all thyroid carcinomas. Τhe median...

   Matthias Lang, Thomas Longerich, Chrysanthi Anamaterou in Thyroid Research

   Article Open access 01 March 2023
   

6. A systematic review of neoadjuvant targeted therapy in locally advanced thyroid cancer

   Introduction

   Locally advanced thyroid cancer refers to thyroid cancer that invades important structures of the neck, with poor prognosis. Neoadjuvant...

   Nai-si Huang, Yu Wang, ... Qing-hai Ji in Holistic Integrative Oncology

   Article Open access 04 November 2022
   

7. Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer

   Pancreatic cancer is one of the deadly malignancies with a significant mortality rate and there are currently few therapeutic options for it. The...

   Pengcheng Zhou, Xuanlong Du, ... Yewei Zhang in Signal Transduction and Targeted Therapy

   Article Open access 24 June 2024
   

8. Recent advancement in targeted therapy and role of emerging technologies to treat cancer

   Cancer is a complex disease that causes abnormal cell growth and spread. DNA mutations, chemical or environmental exposure, viral infections, chronic...

   Shrikant Barot, Henis Patel, ... Igor Ban in Medical Oncology

   Article 07 October 2023
   

9. Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience

   Purpose

   Molecular Profiling of solid tumours is extensively used for prognostic, theranostic, and risk prediction. Next generation sequencing (NGS)...

   Mamta Gurav, Sridhar Epari, ... Sangeeta Desai in Journal of Cancer Research and Clinical Oncology

   Article 20 March 2023
   

10. Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy

    Background

    Chordoma is a rare but devastating tumor that arises in the cranial skull base or spine. There are currently no US Food and Drug...

    Oluwaseun O. Akinduro, Paola Suarez-Meade, ... Alfredo Quiñones-Hinojosa in Targeted Oncology

    Article 24 April 2021
    

11. Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review

    Purpose

    Metastatic renal cell carcinoma (mRCC) still harbours a big propensity for future metastasis. Combinations of immune and targeted therapies...

    Georges Abi Tayeh, Marwan Alkassis, ... Alexandre Ingels in World Journal of Urology

    Article 20 January 2024
    

12. Targeted Therapy for Melanomas Without BRAF V600 Mutations

    Modern therapy of advanced melanoma offers effective targeted therapeutic options in the form of BRAF plus MEK inhibition for patients with BRAF V600...

    Christian Menzer, Jessica C. Hassel in Current Treatment Options in Oncology

    Article Open access 05 April 2022

13. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy

    Purpose

    The combination of gemcitabine-based chemotherapy and immune checkpoint inhibitors has a good efficacy in advanced biliary tract cancer (BTC)....

    **ang Dong, Zewu Zhang, ... Wei Zhang in Journal of Cancer Research and Clinical Oncology

    Article 08 July 2022
    

14. Current understanding of adenoid cystic carcinoma in the gene expression and targeted therapy

    Adenoid Cystic Carcinoma (ACC) has been considered as a "quiet" tumor. It is typically malignancy arising from exocrine glands with poor long-term...

    Quan-Quan Lin, **-Long Sun, ... Qing ** in Holistic Integrative Oncology

    Article Open access 12 April 2023
    

15. Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

    Background

    Financial burden of cancer treatment can negatively affect patients and their families. This study aimed to evaluate the financial toxicity...

    Sena Yamamoto, Chiharu Kondoh, ... Harue Arao in International Journal of Clinical Oncology

    Article Open access 24 February 2024
    

16. Current trends of targeted therapy for oral squamous cell carcinoma

    Oral squamous cell carcinoma (OSCC) is a malignant disease in the world which has a profound effect on human health and life quality. According to...

    Hongjiao Li, Yao Zhang, ... Deqin Yang in Journal of Cancer Research and Clinical Oncology

    Article 02 May 2022
    

17. Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC

    Anaplastic lymphoma kinase ( ALK ) is the most common fusion gene involved in non-small cell lung cancer (NSCLC), and remarkable response has been...

    Wei Rao, Yutao Liu, ... Weihua Li in Frontiers of Medicine

    Article 03 April 2023

18. Targeted Therapy for Melanomas Without BRAF V600 Mutation

    Purpose of Review

    Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for patients with metastatic melanoma; however, there...

    Jacob S. Choi, Sunandana Chandra in Current Oncology Reports

    Article 26 November 2022

19. A pharmacological exploration of targeted drug therapy in non-small cell lung cancer

    Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85% from non-small cell lung cancer. Before a few decades...

    Ajay P. Jayan, K. R. Anandu, ... V. N. Saiprabha in Medical Oncology

    Article 14 July 2022
    

20. Targeted Therapy in Early Stage Non-small Cell Lung Cancer

    Tyrosine kinase inhibitors (TKIs) have dramatically improved tumor response rates and survival benefits in advanced oncogenic non-small-cell lung...

    Si-Yang Liu, Si-Yang Maggie Liu, ... Yi-Long Wu in Current Treatment Options in Oncology

    Article 25 July 2022